Disposition of 5000 shares by Joris Wilms of Y MAbs at 14.69 subject to Rule 16b-3
YMAB Stock | USD 10.01 0.27 2.63% |
About 75% of Y MAbs' investor base is looking to short. The analysis of the overall investor sentiment regarding Y mAbs Therapeutics suggests that many traders are alarmed. The current market sentiment, together with Y MAbs' historical and current headlines, can help investors time the market. In addition, many technical investors use Y mAbs Therapeutics stock news signals to limit their universe of possible portfolio assets.
YMAB |
Filed transaction by Y mAbs Therapeutics Officer: Svp & Chief Operating Officer. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
Read at macroaxis.com
Cash Flow Correlation
Y MAbs' cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Y MAbs' relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.Click cells to compare fundamentals
Y MAbs Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Y MAbs can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Y MAbs Fundamental Analysis
We analyze Y MAbs' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Y MAbs using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Y MAbs based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Operating Margin
Operating Margin Comparative Analysis
Y MAbs is currently under evaluation in operating margin category among its peers. Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Y mAbs Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Y MAbs stock to make a market-neutral strategy. Peer analysis of Y MAbs could also be used in its relative valuation, which is a method of valuing Y MAbs by comparing valuation metrics with similar companies.
Peers
Y MAbs Related Equities
CCCC | C4 Therapeutics | 9.28 | ||||
STRO | Sutro Biopharma | 4.26 | ||||
BDTX | Black Diamond | 2.09 | ||||
MIRM | Mirum Pharmaceuticals | 1.82 | ||||
EWTX | Edgewise Therapeutics | 1.15 | ||||
GBIO | Generation Bio | 0.79 | ||||
PCVX | Vaxcyte | 0.69 | ||||
MRUS | Merus BV | 0.58 | ||||
TVTX | Travere Therapeutics | 0.37 | ||||
DAWN | Day One | 0.45 | ||||
ERAS | Erasca | 0.67 | ||||
RVMD | Revolution Medicines | 1.82 | ||||
MRSN | Mersana Therapeutics | 2.75 | ||||
LRMR | Larimar Therapeutics | 2.81 | ||||
KRON | Kronos Bio | 2.86 | ||||
ARQT | Arcutis Biotherapeutics | 2.89 | ||||
ZNTL | Zentalis Pharmaceuticals | 3.05 | ||||
PASG | Passage Bio | 3.80 | ||||
SNDX | Syndax Pharmaceuticals | 3.98 | ||||
BLUE | Bluebird Bio | 7.14 |
Complementary Tools for YMAB Stock analysis
When running Y MAbs' price analysis, check to measure Y MAbs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Y MAbs is operating at the current time. Most of Y MAbs' value examination focuses on studying past and present price action to predict the probability of Y MAbs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Y MAbs' price. Additionally, you may evaluate how the addition of Y MAbs to your portfolios can decrease your overall portfolio volatility.
Global Correlations Find global opportunities by holding instruments from different markets | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
CEOs Directory Screen CEOs from public companies around the world | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
Equity Valuation Check real value of public entities based on technical and fundamental data |